


Integrating treatment advances for alpha-mannosidosis into effective MDT care

Practice aid for the management of people living with alpha-mannosidosis For more information, visit: <u>www.touchendocrinologyime.org</u>

Treatment needs may vary by clinical subtype and evolve along the lifespan of people living with AM



Consensus recommendations on coordinated care

2024 DELPHI consensus study on monitoring and integrated care⁵

Assessments in newly diagnosed patients	·	Genetic testing	•	Baseline assessments
Routine follow-up and care		Behavioural/psychiatric Biochemical assays Cardiac function CNS manifestation Cognitive impairment Hearing assessments	• • •	Immune function Muscular/motor function Ophthalmologic pathologies Patient-reported outcomes Skeletal abnormalities Other manifestations
Treatment-related follow-up and care		ERT-related monitoring Post-HSCT monitoring	•	Supportive care monitoring Integrated care coordination




"Patients with AM should have a long-term multidisciplinary care team that includes an AM specialist to coordinate the team, as well as a group of specialists with expertise in each patient's specific disease manifestations"



Practice aid for the management of people living with alpha-mannosidosis

Available disease-modifying therapies





Abbreviations and references

Abbreviations

AM, alpha-mannosidosis; CNS, central nervous system; ERT, enzyme replacement therapy; GvHD, graft versus host disease;

HSCT, haematopoietic stem cell transplant; IRR, infusion-related reaction; MDT, multidisciplinary team.

References

- 1. Dewsbury MR, et al. J Transl Genet Genom. 2024;8:85–101.
- 2. Köse E, et al. Eur J Med Genet. 2024;68:104927.
- 3. Ficicioglu C, Stepien KM. In: Adam MP, Feldman J, et al, editors. GeneReviews[®] [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
- 4. Santoro L, et al. *Mol Genet Metab*. 2024;142:108444.
- 5. Guffon M, et al. *Mol Genet Metab.* 2024;142:108519.
- 6. Diaz JCL, et al. Int J Mol Sci. 2022;1:232.
- 7. Ceccarini V, et al. Int J Mol Sci. 2018;19:1500.
- 8. EMA. Velmanase alfa SmPC. Available at: www.ema.europa.eu/en/documents/product-information/lamzede-epar-product-information_en.pdf (accessed 17 March 2025).
- 9. FDA. Velmanase alfa PI. www.accessdata.fda.gov/drugsatfda_docs/label/2023/761278s000lbl.pdf (accessed 17 March 2025).
- 10. Guffon N, et al. J Inherit Metab Dis. 2025;48:e12799.
- 11. Naumchik BM, et al. Cells. 2020;9:1411.
- 12. Mynarek M, et al. Bone Marrow Transplant. 2012;47:352-9.

The guidance provided by this practice aid is not intended to directly influence patient care. Clinicians should always evaluate their patients' conditions and potential contraindications and review any relevant manufacturer product information or recommendations of other authorities prior to consideration of procedures, medications, or other courses of diagnosis or therapy included here.

Our practice aid coverage does not constitute implied endorsement of any product(s) or use(s). touchENDOCRINOLOGY cannot guarantee the accuracy, adequacy or completeness of any information and cannot be held responsible for any errors or omissions.

